Analysts Offer Insights on Healthcare Companies: Flexion Therapeutics (NASDAQ: FLXN) and Alnylam Pharma (NASDAQ: ALNY)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Flexion Therapeutics (NASDAQ: FLXN) and Alnylam Pharma (NASDAQ: ALNY) with bullish sentiments.

Flexion Therapeutics (NASDAQ: FLXN)

BMO Capital analyst Gary Nachman reiterated a Buy rating on Flexion Therapeutics (NASDAQ: FLXN) yesterday and set a price target of $35. The company’s shares closed yesterday at $21.74.

According to TipRanks.com, Nachman is a 4-star analyst with an average return of 13.0% and a 64.8% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Sucampo Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Flexion Therapeutics is Moderate Buy and the average price target is $35, representing a 61.0% upside.

In a report issued on June 12, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $40 price target.
Alnylam Pharma (NASDAQ: ALNY)

BMO Capital analyst Do Kim reiterated a Buy rating on Alnylam Pharma (NASDAQ: ALNY) yesterday and set a price target of $105. The company’s shares closed yesterday at $82.92, close to its 52-week high of $86.92.

According to TipRanks.com, Kim is a 5-star analyst with an average return of 24.0% and a 77.3% success rate. Kim covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Vertex Pharmaceuticals, and Cynapsus Therapeutics.

Currently, the analyst consensus on Alnylam Pharma is Moderate Buy and the average price target is $87.50, representing a 5.5% upside.

In a report issued on June 12, Chardan Capital also reiterated a Buy rating on the stock with a $110 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.